Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(4), P. 1291 - 1291
Published: Feb. 15, 2025
Background:
Systemic
advanced
therapies,
including
biologic
drugs
and
Janus
kinase
(JAK)
inhibitors,
have
revolutionized
atopic
dermatitis
management.
The
increasing
number
of
available
options
for
such
complex
diseases
demands
careful
treatment
selection
each
patient,
considering
numerous
variables.
Comparative
analyses
these
modalities
in
the
real
world
are
still
limited.
Only
a
faithful
basal
characterization
would
enable
posterior
meaningful
accurate
comparisons
efficacy
safety
profiles
groups
drugs.
This
communication
focuses
on
describing
comparing
baseline
demographics
comorbidities
patients
with
currently
treated
therapies
versus
JAK
inhibitors
our
setting.
Methods:
We
conducted
an
observational,
descriptive,
ambispective
study
across
three
hospitals
covering
population
over
500,000
inhabitants
from
January
2019
to
December
2024.
Baseline
demographic
data,
anthropometric
measures,
lifestyle
factors,
cardiovascular
risk
were
analyzed
using
descriptive
inferential
statistics.
Additionally,
severity
effectivity
time
also
been
compared.
Results:
A
total
150
analyzed.
102
had
received
biological
(dupilumab
or
tralokinumab),
whereas
48
(upadacitinib,
baricitinib,
abrocitinib).
Ages
ranged
11
76
years.
overall
cohort
mean
age
35.87
±
14.37
years
male
predominance
(male-to-female
ratio
1.63:1).
Hypertension
was
more
prevalent
group
(p
=
0.0175),
yet
other
body
measurements,
non-atopic
comorbidities,
disease
comparable
both
groups.
Conclusions:
helped
characterize
characteristics
systemic
real-world
clinical
It
pointed
just
slight
differences
between
biologics
inhibitors.
homogeneity
sets
ground
further
future
outcomes
this
as
potential
confounding
factors
related
imbalances
minimized.
Language: Английский
Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(7), P. 2895 - 2895
Published: March 22, 2025
Psoriasis
is
a
chronic
immune-mediated
skin
disease
characterized
by
cytokine
dysregulation.
Pro-inflammatory
mediators,
including
tumor
necrosis
factor-alpha
(TNF-α),
interleukin
(IL)-17,
and
IL-23,
play
pivotal
roles
in
the
pathogenesis
of
psoriasis.
Emerging
evidence
suggests
that
dietary
interventions
can
modulate
activity,
providing
complementary
approach
to
standard
therapies.
This
narrative
review
examines
impact
various
strategies,
Mediterranean
diet,
ketogenic
gluten-free
fasting-mimicking
on
profiles
clinical
outcomes
Research
insights
reveal
components
such
as
omega-3
fatty
acids,
polyphenols,
short-chain
acids
influence
immune
signaling
pathways.
These
pathways
include
nuclear
factor-kappa
B
(NF-κB)
Signal
Transducer
Activator
Transcription
3
(STAT3).
Additionally,
these
promote
anti-inflammatory
effects
mediated
gut
microbiota.
Clinical
studies
demonstrate
significant
reductions
psoriasis
severity,
improved
quality
life,
modulation
key
cytokines
associated
with
activity.
Despite
advancements,
challenges
persist
effectively
integrating
findings
into
practice.
variability
patient
responses,
adherence
issues,
need
for
robust
biomarkers
monitor
efficacy.
Future
directions
emphasize
potential
personalized
nutrition
precision
medicine
approaches
optimize
tailored
individual
genetic
predispositions.
Integrating
strategies
care
could
transform
treatment
paradigms
simultaneously
addressing
both
systemic
inflammation
comorbid
conditions.
Language: Английский